Pearl Therapeutics has won a 2012 TiE50 award from the Indus Entrepreneurs (TiE). Pearl was one of ten winners in the life sciences category. Pearl develops inhaled therapies based on its proprietary particle engineering technology.
Pearl CEO Chuck Bramlage said, “The TiE organization awards start-ups that put a premium on entrepreneurial spirit, technological excellence and business progression. At Pearl, we share the importance TiE places on these values. Since our first funding in 2007, we have built an experienced team of professionals in clinical, regulatory, product development, quality, business and finance; raised over $100 million in venture capital; and discovered solutions to unaddressed drug development and drug delivery challenges. These elements have allowed us to progress a family of bronchodilator products for COPD patients while conforming to the strictest product development standards and maintaining a capital efficient business plan. We believe that these foundations will serve us well as we prepare to enter late stage clinical development, and will provide a return on the capital invested in the company thus far.”
Read the Pearl Therapeutics press release.